KDM1A and Alzheimer disease: ORY-2001, one of the LSD1 inhibitors, has completed the phase IIa clinical trial in patients diagnosed with mild to moderate AD and undergone the phase IIa clinical trial in patients diagnosed with moderate to severe AD [40, 41].